Navigation Links
Tyco International Reports Second Quarter Earnings from Continuing Operations Before Special Items of $0.55 Per Share; Impact of Special Items Results in Loss From Continuing Operations of $5.40 Per Share
Date:4/30/2009

SCHAFFHAUSEN, Switzerland, April 30 /PRNewswire-FirstCall/ --

    ($ millions, except per-share amounts)

                                                Q2 2009  Q2 2008  % Change
                                                -------  -------  --------
    Revenue                                     $4,150   $4,863      (15%)
    (Loss) / Income from Continuing Operations ($2,555)    $272         -
    Diluted EPS from Continuing Operations      ($5.40)   $0.56
    Special Items                               ($5.95)  ($0.11)
    Income from Continuing Ops Before Special
     Items                                        $261     $325      (20%)
    Diluted EPS from Continuing Ops Before
     Special Items                               $0.55    $0.67      (18%)

Tyco International Ltd. (NYSE: TYC) today reported a loss of $5.40 in diluted earnings per share (EPS) from continuing operations for the fiscal second quarter of 2009 and diluted EPS from continuing operations before special items of $0.55 per share. Revenue in the quarter of $4.2 billion declined 15% versus the prior year, mostly due to the impact of the stronger U.S. dollar against foreign currencies. Organic revenue declined 5.5% in the quarter.

Second quarter income from continuing operations was negatively impacted by special items, which totaled $2.8 billion after tax or $5.95 per share as follows:


                                                 After Tax
                                                 ---------  $Per Share
                                              $in Millions  -----------
                                              -------------
    Goodwill and Intangible Asset Impairments       $2,637       $5.56
    Legacy Legal Matters                              $105       $0.23
    Restr
'/>"/>
SOURCE Tyco International Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Cambridge Scientists Archive 500,000th Crystal Structure 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Covance Inc Invites You to Join the Webcast of Its Second Quarter 2009 Financial Results Conference Call 50805 1Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 1Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 2Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 3Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 1Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 2Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 3